Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review.

By John R. Geddes, S. Carney, C. Davies, T. Furukawa, David J. Kupfer, E. Frank, Guy M. Goodwin. The Lancet, 2003

863 citations recorded by the source corpus.

Subfields: Applied Psychology, Pharmacology, Social Psychology

View Paper: https://www.semanticscholar.org/paper/74efe96a2b58774d2d1be35a944beb8fb7e1ee97

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Applied Psychology

1. R. Morriss
2. E. Watkins
3. Peter S. Dayan
4. W. Kuyken
5. S. Gilbody

In Pharmacology

1. Quentin J. M. Huys
2. E. Watkins
3. J. Teasdale
4. Marcus Munafò
5. Jonathan P. Roiser
6. S. Gilbody
7. Oliver D. Howes
8. J. M. G. Williams

In Social Psychology

1. Emily A. Holmes
2. E. Watkins
3. Peter S. Dayan
4. W. Kuyken
5. Marcus Munafò
6. S. Gilbody
7. Oliver D. Howes

Citations in the corpus

• Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. (2008, background): “First, given that m-ADM over at least 2 years is recommended to prevent relapse/ recurrence (Geddes et al., 2003; NICE, 2004) and many patients express a preference for an alternative approach, it is important to establish whether MBCT enables patients to taper/discontinue ADM.”
• Bonsai Trees in Your Head: How the Pavlovian System Sculpts Goal-Directed Choices by Pruning Decision Trees (2012, background): “On the one hand, drugs that putatively increase serotonin by inhibiting the serotonin reuptake mechanism are effective for both acutely treating [28], and preventing relapse of [29], depression.”
• Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines (2015, methodology): “A meta-analysis of discontinuation RCTs in patients with mainly recurrent depression found that 60% of patients on placebo relapsed in the year after randomisation and 29% relapsed in months 12–36 (Geddes et al., 2003).”
• Evidence-based guidelines for treating bipolar disorder: revised third edition Recommendations from the British Association for Psychopharmacology (2009, positive): “The evidence supporting their use in the long-term prophylaxis of unipolar depression is strong (I, (Geddes et al., 2003)).”
• Communicating evidence for participatory decision making. (2004, background): “A systematic review of 31 randomized trials comparing antidepressant continuation with discontinuation concluded that continuing antidepressants reduced the risk of relapse within the next 12 months.(32) The average risk of relapse across trials was 18% with active treatment and 41% with placebo (nu”